Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$14.93
-3.6%
$15.55
$5.70
$22.90
$29.36M1.4640,381 shs17,120 shs
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
$3.23
+4.0%
$2.92
$2.67
$6.24
$28.54M1.236,497 shs75,314 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
+13.15%+11.20%-5.20%-7.25%+1,548,999,900.00%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
+0.32%+8.01%+2.65%+2.31%-39.26%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.0378 of 5 stars
3.53.00.00.00.61.70.6
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
1.8565 of 5 stars
3.33.00.00.03.60.00.0
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
3.00
Buy$32.00114.41% Upside
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
2.50
Moderate Buy$12.00272.09% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INNVD, DARE, CVKD, and PXSLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/1/2025
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$8.86 per shareN/A
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
$25.91K1,101.60N/AN/A($0.61) per share-5.29
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$8.36M-$9.26N/AN/AN/AN/A-142.95%-118.40%8/6/2025 (Estimated)
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A

Latest INNVD, DARE, CVKD, and PXSLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/8/2025Q1 2025
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.64-$2.09-$0.45-$2.09N/AN/A
3/31/2025Q4 2024
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million
3/13/2025Q4 2024
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.71-$2.74-$1.03-$2.74N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
3.69
3.69
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
N/A
1.14
1.14
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92

Institutional Ownership

CompanyInstitutional Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
6.70%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A

Insider Ownership

CompanyInsider Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
48.62%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
4.00%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
41.97 million916,000Not Optionable
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
308.85 million8.35 millionNot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$14.92 -0.57 (-3.65%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Daré Bioscience stock logo

Daré Bioscience NASDAQ:DARE

$3.22 +0.13 (+4.03%)
As of 02:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.